E-submission
Search
- Page Path
- HOME > Search
Original Articles
- Clinicopathologic Significance of Survivin Expression in Relation to CD133 Expression in Surgically Resected Stage II or III Colorectal Cancer
- Wanlu Li, Mi-Ra Lee, EunHee Choi, Mee-Yon Cho
- J Pathol Transl Med. 2017;51(1):17-23. Published online December 15, 2016
- DOI: https://doi.org/10.4132/jptm.2016.09.23
- 8,714 View
- 167 Download
- 17 Web of Science
- 17 Crossref
-
Abstract
PDF - Background
Cancer stem cells have been investigated as new targets for colorectal cancer (CRC) treatment. We recently reported that CD133+ colon cancer cells showed chemoresistance to 5-fluorouracil through increased survivin expression and proposed the survivin inhibitor YM155 as an effective therapy for colon cancer in an in vitro study. Here, we investigate the relationship between survivin and CD133 expression in surgically resected CRC to identify whether the results obtained in our in vitro study are applicable to clinical samples.
Methods
We performed immunohistochemical staining for survivin and CD133 in surgically resected tissue from 187 stage II or III CRC patients. We also comparatively analyzed apoptosis according to survivin and CD133 expression using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling.
Results
The results of the Mantel-Haenszel test established a linear association between nuclear survivin and CD133 expression (p = .018), although neither had prognostic significance, according to immunohistochemical expression level. No correlation was found between survivin expression and the following pathological parameters: invasion depth, lymph node metastasis, or histologic differentiation (p > .05). The mean apoptotic index in survivin+ and CD133+ tumors was higher than that in negative tumors: 5.116 ± 4.894 in survivin+ versus 4.103 ± 3.691 in survivin– (p = .044); 5.165 ± 4.961 in CD133+ versus 4.231 ± 3.812 in CD133– (p = .034).
Conclusions
As observed in our in vitro study, survivin expression is significantly related to CD133 expression. Survivin may be considered as a new therapeutic target for chemoresistant CRC. -
Citations
Citations to this article as recorded by
- Upregulation of EMR1 (ADGRE1) by Tumor-Associated Macrophages Promotes Colon Cancer Progression by Activating the JAK2/STAT1,3 Signaling Pathway in Tumor Cells
Rokeya Akter, Rackhyun Park, Soo Kyung Lee, Eun ju Han, Kyu-Sang Park, Junsoo Park, Mee-Yon Cho
International Journal of Molecular Sciences.2024; 25(8): 4388. CrossRef - Antiapoptotic Gene Genotype and Allele Variations and the Risk of Lymphoma
Osama M. Al-Amer, Rashid Mir, Abdullah Hamadi, Mohammed I. Alasseiri, Malik A. Altayar, Waseem AlZamzami, Mamdoh Moawadh, Sael Alatawi, Hanan A. Niaz, Atif Abdulwahab A. Oyouni, Othman R. Alzahrani, Hanan E. Alatwi, Aishah E. Albalawi, Khalaf F. Alsharif,
Cancers.2023; 15(4): 1012. CrossRef - The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer
Getinet M. Adinew, Samia Messeha, Equar Taka, Karam F. A. Soliman
Cancers.2022; 14(21): 5180. CrossRef - EMR1/ADGRE1 Expression in Cancer Cells Upregulated by Tumor-Associated Macrophages Is Related to Poor Prognosis in Colorectal Cancer
Rokeya Akter, Kwangmin Kim, Hye Youn Kwon, Youngwan Kim, Young Woo Eom, Hye-mi Cho, Mee-Yon Cho
Biomedicines.2022; 10(12): 3121. CrossRef - Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts
Nina Oparina, Malin C. Erlandsson, Anna Fäldt Beding, Toshima Parris, Khalil Helou, Per Karlsson, Zakaria Einbeigi, Maria I. Bokarewa
Cancers.2021; 13(9): 2209. CrossRef - Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin Signaling
Chi-Hung R. Or, Chiao-Wen Huang, Ching-Chin Chang, You-Chen Lai, Yi-Ju Chen, Chia-Che Chang
International Journal of Molecular Sciences.2020; 21(5): 1773. CrossRef - M1 Macrophages Promote TRAIL Expression in Adipose Tissue-Derived Stem Cells, Which Suppresses Colitis-Associated Colon Cancer by Increasing Apoptosis of CD133+ Cancer Stem Cells and Decreasing M2 Macrophage Population
Young Woo Eom, Rokeya Akter, Wanlu Li, Suji Lee, Soonjae Hwang, Jiye Kim, Mee-Yon Cho
International Journal of Molecular Sciences.2020; 21(11): 3887. CrossRef - Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics
Neerada Meenakshi Warrier, Prasoon Agarwal, Praveen Kumar
Stem Cell Reviews and Reports.2020; 16(5): 828. CrossRef - MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression
Jaime A. Oliver, Raúl Ortiz, Cristina Jiménez-Luna, Laura Cabeza, Gloria Perazzoli, Octavio Caba, Cristina Mesas, Consolación Melguizo, Jose Prados
Journal of Biosciences.2020;[Epub] CrossRef - Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case–control studies
Abdolkarim Moazeni-Roodi, Saeid Ghavami, Mohammad Hashemi
International Journal of Clinical Oncology.2019; 24(4): 335. CrossRef - CRISPR-Cas9 mediated CD133 knockout inhibits colon cancer invasion through reduced epithelial-mesenchymal transition
Wanlu Li, Mee-Yon Cho, Suji Lee, Mirae Jang, Junsoo Park, Rackhyun Park, Aamir Ahmad
PLOS ONE.2019; 14(8): e0220860. CrossRef - Diagnostic Approaches for Salivary Gland Tumors with Secretory and Microcystic Features
Ha Young Woo, Eun Chang Choi, Sun Och Yoon
Head and Neck Pathology.2018; 12(2): 237. CrossRef - MUC1‐ and Survivin‐based DNA Vaccine Combining Immunoadjuvants CpG and interleukin‐2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model
C. Liu, Y. Xie, B. Sun, F. Geng, F. Zhang, Q. Guo, H. Wu, B. Yu, J. Wu, X. Yu, W. Kong, H. Zhang
Scandinavian Journal of Immunology.2018; 87(2): 63. CrossRef - Activated STAT3 may participate in tumor progression through increasing CD133/survivin expression in early stage of colon cancer
Wanlu Li, Mi-Ra Lee, Taeyeong Kim, Young Wan Kim, Mee-Yon Cho
Biochemical and Biophysical Research Communications.2018; 497(1): 354. CrossRef - MiRNA-142-3p increases radiosensitivity in human umbilical cord blood mononuclear cells by inhibiting the expression of CD133
Fang Yuan, Lu Liu, Yonghong Lei, Yi Hu
Scientific Reports.2018;[Epub] CrossRef - MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway
Yue Li, Shihong Zhang, Yuanjian Wang, Jin Peng, Fang Fang, Xingsheng Yang
BMC Cancer.2018;[Epub] CrossRef - Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry
Shunsuke Itai, Yuki Fujii, Takuro Nakamura, Yao-Wen Chang, Miyuki Yanaka, Noriko Saidoh, Saori Handa, Hiroyoshi Suzuki, Hiroyuki Harada, Shinji Yamada, Mika K. Kaneko, Yukinari Kato
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy.2017; 36(5): 231. CrossRef
- Upregulation of EMR1 (ADGRE1) by Tumor-Associated Macrophages Promotes Colon Cancer Progression by Activating the JAK2/STAT1,3 Signaling Pathway in Tumor Cells
- Clinicopathological Significance of Invasive Ductal Carcinoma with High Prevalence of CD44(+)/CD24(-/low) Tumor Cells in Breast Cancer.
- Ji Youn Sung, Gou Young Kim, Yong Koo Park, Juhie Lee, Youn Wha Kim, Sung Jig Lim
- Korean J Pathol. 2010;44(4):390-396.
- DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.4.390
- 3,459 View
- 22 Download
- 2 Crossref
-
Abstract
PDF
- BACKGROUND
Epithelial tumor cells with a CD44(+)/CD24(-/low) immunoprofile may have the ability to cause breast cancer. We studied these cells and their clinicopathological significance.
METHODS
The clinicopathologic findings of 100 invasive ductal carcinoma (IDC) cases and 45 ductal carcinoma in situ (DCIS) cases were reviewed. CD44(+)/CD24(-/low) tumor cells were identified by immunohistochemistry, and their clinicopathological implications in IDC and DCIS were analyzed.
RESULTS
IDC with a high prevalence of CD44(+)/CD24(-/low) tumor cells was significantly associated with larger mass, higher grade, estrogen receptor (ER) negativity, and tumor cells with a higher frequency of metastasis. The proportion of CD44(+)/CD24(-/low) tumor cells in IDC, and its DCIS components was not significantly different, whereas the proportion of CD44(+)/CD24(-/low) tumor cells was higher in DCIS than in the DCIS component of IDC (p < 0.001).
CONCLUSIONS
IDC with a high prevalence of CD44(+)/CD24(-/low) tumor cells might correlate with aggressive features, such as ER and higher grades. Moreover, the proportion of CD44(+)/CD24(-/low) tumor cells in the DCIS components of IDC and DCIS might harbor different biology, which may lead to differences in cancer progression and early carcinogenesis. -
Citations
Citations to this article as recorded by- Clinicopathologic Characteristics of Breast Cancer Stem Cells Identified on the Basis of Aldehyde Dehydrogenase 1 Expression
Yoon Seok Kim, Min Jung Jung, Dong Won Ryu, Chung Han Lee
Journal of Breast Cancer.2014; 17(2): 121. CrossRef - CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy
Agnieszka Adamczyk, Joanna A. Niemiec, Aleksandra Ambicka, Anna Mucha-Małecka, Jerzy Mituś, Janusz Ryś
Journal of Molecular Histology.2014; 45(1): 35. CrossRef
- Clinicopathologic Characteristics of Breast Cancer Stem Cells Identified on the Basis of Aldehyde Dehydrogenase 1 Expression
First
Prev
